Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Biosecurity

    DARPA Awards ‘Safe Genes’ Contract to Mass Gen

    By Global Biodefense StaffJune 6, 2017
    Safe Genes: DARPA Gene Editing Program
    Credit: DARPA, adapted.
    Share
    Facebook LinkedIn Reddit Email

    The Defense Advanced Research Projects Agency (DARPA) has awarded a cooperative agreement to Massachusetts General Hospital for research and development supporting the Safe Genes program.

    The Safe Genes program aims to deliver novel biological capabilities to facilitate the safe and expedient pursuit of advanced genome editing applications, while also providing the tools and methodologies to mitigate the risk of unintentional consequences or intentional misuse of these technologies.

    There are three primary technical focus areas within the Safe Genes program to help bridge the gap between the current technological landscape and the future transformative applications of genome editing tools and engineered organisms. First, researchers will design and develop the genetic circuitry and genome editing machinery for robust, spatial, temporal, and reversible control of genome editing activity in living systems.

    The second technical focus area will develop small molecules and/or molecular strategies to provide prophylactic and treatment solutions that prevent or limit genome editing activity and protect the genome integrity of organisms and populations.

    Finally, researchers will develop “genetic remediation” strategies that eliminate unwanted engineered genes from a broad range of complex population and environmental contexts to restore systems to functional and genetic baseline states. Overall the program aims to create a layered, modular, and adaptable solution set to access translational applications of genome editing technologies while protecting against intentional or accidental misuse of these tools.

    The contract has a ceiling value of $11,000,660. The scope of Massachusetts General Hospital’s work under the Safe Gene program is unspecified.

    Work will be performed in Boston, Massachusetts (51 percent); London, United Kingdom (24 percent); Raleigh, North Carolina (8 percent); and Perugia, Italy (17 percent), with an expected completion date of April 2021. Fiscal 2016 funds in the amount of $987,271 are being obligated at time of award.

    This was a competitive acquisition and 17 offers were received. The Defense Advanced Research Projects Agency, Arlington, Virginia, is the contracting activity (HR0011-17-2-0042).

    Source: Defense.gov, Darpa.mil

    Awards CRISPR DARPA Dual Use Research of Concern (DURC) Synthetic Biology
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleBiodefense Headlines – June 4, 2017
    Next Article MV-CHIKV Chikungunya Vaccine Clinical Trial Begins

    Related Stories

    ARPA-H Announces New Tiered Proposal Submission System to Reduce Applicant Barriers

    December 5, 2023

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    APHIS Announces Funding for Tribes to Support Animal Disease Preparedness and Response

    October 24, 2023

    USDA APHIS Announces Partnership to Improve Early Detection of Emerging Animal Diseases

    October 17, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.